CureVac is developing a COVID-19 vaccine that uses messenger RNA taken from the novel coronavirus to create antibodies in the bloodstream. Tesla plans to produce what Mr. Musk called “RNA microfactories” to support the project.
“In principle, I think synthetic RNA (and DNA) has amazing potential. This basically makes the solution to many diseases a software problem,” Mr. Musk wrote.
Other drugmakers utilizing an RNA-centric approach to their vaccine efforts include Moderna and BioNTech.
More articles on pharmacy:
FDA releases guidance on COVID-19 vaccine approval: 4 things to know
Novartis to pay $678M to settle kickback lawsuit
Gilead’s remdesivir pricing could set a disruptive industry precedent
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.